- Home
- GH vs LBTYK Comparison
GH vs LBTYK Comparison
Compare GH & LBTYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | LBTYK |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GH | LBTYK |
|---|---|---|
| Price | $103.60 | $11.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $79.19 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 932.3K |
| Earning Date | 10-29-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $902,569,000.00 | ★ $4,770,600,000.00 |
| Revenue This Year | $34.72 | $13.25 |
| Revenue Next Year | $26.46 | $1.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 30.38 | ★ 170.50 |
| 52 Week Low | $29.91 | $9.21 |
| 52 Week High | $112.43 | $14.76 |
Technical Indicators
Market Signals| Indicator | GH | LBTYK |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 56.65 |
| Support Level | $98.23 | $11.26 |
| Resistance Level | $112.43 | $11.53 |
| Average True Range (ATR) | 5.44 | 0.27 |
| MACD | -0.54 | 0.07 |
| Stochastic Oscillator | 64.46 | 74.74 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.